In the last trading session, 1.06 million Arcus Biosciences Inc (NYSE:RCUS) shares changed hands as the company’s beta touched 0.89. With the company’s per share price at $16.97 changed hands at -$1.47 or -7.97% during last session, the market valuation stood at $1.55B. RCUS’s last price was a discount, traded about -19.68% off its 52-week high of $20.31. The share price had its 52-week low at $12.95, which suggests the last value was 23.69% up since then. When we look at Arcus Biosciences Inc’s average trading volume, we note the 10-day average is 0.77 million shares, with the 3-month average coming to 598.10K.
Analysts gave the Arcus Biosciences Inc (RCUS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.58. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RCUS as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcus Biosciences Inc (NYSE:RCUS) trade information
Instantly RCUS was in red as seen at the end of in last trading. With action -6.19%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -11.15%, with the 5-day performance at -6.19% in the red. However, in the 30-day time frame, Arcus Biosciences Inc (NYSE:RCUS) is 2.97% up. Looking at the short shares, we see there were 6.61 million shares sold at short interest cover period of 12.52 days.
The consensus price target for the stock as assigned by Wall Street analysts is 32, meaning bulls need an upside of 46.97% from its current market value. According to analyst projections, RCUS’s forecast low is 20 with 44 as the target high. To hit the forecast high, the stock’s price needs a -159.28% plunge from its current level, while the stock would need to soar -17.86% for it to hit the projected low.
Arcus Biosciences Inc (RCUS) estimates and forecasts
Data shows that the Arcus Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 15.60% over the past 6 months, a 21.45% in annual growth rate that is considerably higher than the industry average of 17.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -23.70%. The 2024 estimates are for Arcus Biosciences Inc earnings to increase by 23.20%, but the outlook for the next 5-year period is at 7.80% per year.
RCUS Dividends
Arcus Biosciences Inc is expected to release its next quarterly earnings report on 2024-Nov-05.
Arcus Biosciences Inc (NYSE:RCUS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 40.64% of Arcus Biosciences Inc shares while 58.42% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 98.42%. There are 58.42% institutions holding the Arcus Biosciences Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 11.3261% of the shares, roughly 9.76 million RCUS shares worth $148.69 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.099% or 5.26 million shares worth $80.07 million as of 2024-06-30.
